Amarantus' CEO to Host Twitter Chat on Thursday, July 10, 2014 at 4pm EDT
July 07 2014 - 4:25PM
Amarantus BioScience Holdings, Inc. (OTCBB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to endoplasmic reticulum
stress, cell cycle dysregulation, neurodegeneration and apoptosis,
today announced that Gerald Commissiong, President and CEO will
host and participate in a Twitter chat on Thursday, July 10, 2014
from 4-4:30pm EDT via his Twitter handle @G_Commish.
All investors, analysts, and industry professionals that are
interested in learning more about Amarantus BioScience and the
upcoming #C4CT Concussion Awareness Summit on July 31, 2014 are
invited to submit questions and follow the chat on Twitter.com. Mr.
Commissiong will try to answer as many of the user submitted
questions as possible during the chat.
Questions may be submitted prior to and during the event via
Twitter using #AskAMBS.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready
indication for Parkinson's Levodopa induced dyskinesia and Adult
ADHD. AMBS has an exclusive worldwide license to the Lymphocyte
Proliferation test ("LymPro Test(R)") for Alzheimer's disease and
owns the intellectual property rights to a therapeutic protein
known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF") and is developing MANF-based products as treatments for
brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
Forward Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements." These forward-looking statements
generally are identified by the words believes," project,"
expects," anticipates," estimates," intends," strategy," plan,"
may," will," would," will be," will continue," will likely result,"
and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and
uncertainties which may cause actual results to differ materially
from the forward-looking statements. Our ability to predict results
or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on
our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest
rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in
evaluating forward-looking statements and undue reliance should not
be placed on such statements.
CONTACT: Investor/Media Contacts
Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc.
408-737-2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024